Form 4: Aligos Therapeutics Director Acquires Stock Options
Statement of Changes in Beneficial Ownership
Margarita Chavez, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock.
Summary
- Margarita Chavez, a Director of Aligos Therapeutics, Inc., acquired stock options on June 25, 2026.
- The options grant the right to purchase 5,860 shares of common stock at an exercise price of $5.50 per share.
- These options are set to expire on June 25, 2036.
- The shares subject to the option will vest 100% on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, provided continuous service to the Issuer through the vesting date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and incentive mechanism for a company director rather than a significant strategic or financial development.
Positives
- Director acquisition of stock options can signal confidence in the company's future prospects.
- The acquisition is structured as an option grant, which is a common form of executive compensation.
Future Outlook
The stock options are subject to vesting conditions tied to continuous service and specific future dates, indicating a forward-looking incentive for the director.
Industry Context
StockSavvy.ai notes that the acquisition of stock options by a director is a routine event for companies in the biotechnology and pharmaceutical sectors, often used to align executive interests with shareholder value over the long term.
Stakeholder Impact
- Shareholders: The acquisition of options by a director may be viewed positively as it aligns management's interests with long-term company performance.
Next Steps
- Vesting of stock options on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, subject to continuous service.
Key Dates
| Date | Description |
|---|---|
| 06/25/2026 | Transaction Date (Acquisition of Stock Options) |
| 06/25/2036 | Expiration Date of Stock Options |
| 2027 | Potential vesting date for stock options (prior to annual meeting) |
Keywords
Form 4, SEC Filing, Stock Options, Insider Trading, Aligos Therapeutics, Director, Beneficial Ownership, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.